Rein Therapeutics, Inc..
RNTX.US | Research and experimental development on natural sciences and engineering
Rein Therapeutics, Inc. is a biotechnology company focused on the discovery and development of novel cancer therapies. The company's primary focus is on developing innovative treatments for various types of cancer, including solid tumors and hematological malignancies. Rein Therapeutics utilizes its...Show More
Better Health for All
0
No evidence available to assess Rein Therapeutics, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
No evidence available to assess Rein Therapeutics, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess Rein Therapeutics, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Rein Therapeutics, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-10
Rein Therapeutics has a whistleblower policy allowing employees to report violations openly or anonymously without fear of retaliation, unless the report was made with knowledge that it was false.
1
A toll-free number (866-869-5217), mail, and an online portal are available for reporting concerns regarding accounting, internal controls, auditing matters, or code violations.
2
The company has not had any financial restatements in the past five years. In April 2025, the Board determined that all directors, except for Dr. Windsor and Dr. Aivado, are independent as defined by Nasdaq rules.
3
The company has an anti-corruption policy that prohibits bribes and kickbacks and states compliance with the Foreign Corrupt Practices Act.
4
However, there is no information on the frequency or effectiveness of training for this policy.
Kind to Animals
0
The provided articles do not contain any specific, concrete data points or mentions related to Rein Therapeutics, Inc.'s animal testing policies, volume of animals used in testing, use of alternative testing methods, cruelty-free certifications, humane certifications for operations, wildlife conservation impact, ethical input substitution, supplier audits for welfare compliance, cage-free sourcing, innovation investment in animal-free technologies, animal agriculture ethics, animal-free R&D collaboration, or public policy engagement on animal welfare.
1
Therefore, no KPIs under the 'Kind to Animals' value can be scored based on the evidence provided.
No War, No Weapons
0
The provided articles describe Rein Therapeutics, Inc. as a biotechnology company focused on developing novel therapies for orphan pulmonary and fibrosis indications.
1
The company's product candidates include LTI-03 for Idiopathic Pulmonary Fibrosis and LTI-01 for loculated pleural effusion.
2
The articles detail financial information, SEC filings, and regulatory designations (Orphan Drug Designation) but contain no explicit information regarding any involvement in arms manufacturing, military contracts, dual-use technologies, sales to sanctioned regimes, peacebuilding investments, or any other activities directly related to the 'No War, No Weapons' value.
3
As no specific, concrete data points are provided for any of the KPIs, all KPIs must be omitted.
Planet-Friendly Business
0
The provided articles for Rein Therapeutics (RNTX.US) focus on financial performance, clinical trial updates, patent grants, and a regulatory clinical hold by the FDA. None of the articles contain any specific, quantitative data or information related to environmental performance, climate targets, resource consumption, waste management, or any other 'Planet-Friendly Business' metrics.
1
Therefore, no KPIs under this category can be scored based on the evidence provided.
Respect for Cultures & Communities
0
No evidence available to assess Rein Therapeutics, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
Rein Therapeutics demonstrates good regulatory compliance. The FDA lifted a full clinical hold on the company's Phase 2 trial for LTI-03 after reviewing Rein's submission and confirming that all prior concerns were fully resolved.
1
The company also references compliance with various regulations including SEC requirements, the Trust Indenture Act of 1939, Sarbanes-Oxley Act of 2002, Foreign Corrupt Practices Act of 1977, Currency and Foreign Transactions Reporting Act of 1970, European Union General Data Protection Regulation (GDPR), and U.S. Food and Drug Administration (FDA) regulations.
2
Zero Waste & Sustainable Products
0
No specific, concrete evidence was found in the provided articles regarding Rein Therapeutics, Inc.'s performance across any of the 'Zero Waste & Sustainable Products' KPIs.
1
The articles either discuss general industry trends within the biopharmaceutical sector or explicitly state the absence of company-specific data for RNTX.US.